Your Messages Inbox
Your Article Summary
See Latest ArticlesARIADs AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
ARIAD Pharmaceuticals, 11/03/09
ARIAD Pharmaceuticals, Inc. announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD's investigational, multi–targeted kinase inhibitor. The paper, “AP24534, a Pan–BCR–ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation–Based Resistance,” is co–authored by scientists from ARIAD, and collaborating investigators from the Oregon Health & Science University Knight Cancer Institute and the Howard Hughes Medical Institute.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor